Key result
Higher circulating visfatin linked to ~9% greater risk of renal events in nondiabetic hypertensive patients.
Why the study?
Are circulating visfatin levels associated with subsequent decline in renal function in nondiabetic hypertensive patients?
Cohort (n=200)
Are circulating visfatin levels associated with subsequent decline in renal function in nondiabetic hypertensive patients?
Answers are grounded in this paper and cite their sources.
Increased circulating visfatin is an independent predictor of renal function decline and future renal events in nondiabetic hypertensive patients.
BACKGROUD: Declining renal function is an independent risk factor for all-cause mortality in cardiovascular disease. Visfatin has been described as a marker of inflammation and endothelial dysfunction, but whether circulating visfatin levels are predictive to a subsequent decline in renal function remains unclear. METHODS: In total, 200 nondiabetic, non-proteinuric hypertensive outpatients with initial serum creatinine (Scr) ≤1.5 mg/dl were enrolled. Plasma visfatin concentration and endothelial function estimated by brachial artery flow-mediated dilatation (FMD) were determined in the study subjects. The primary endpoints were the occurrence of renal events including doubling of Scr, 25% loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease during follow-up. RESULTS: The mean annual rate of GFR decline (ΔGFR/y) was -1.26±2.76 ml/min/1.73 m(2) per year during follow-up (8.6±2.5 years). At baseline, plasma visfatin was negatively correlated with estimated GFR. In longitudinal analysis, the ΔGFR/y was correlated with visfatin, baseline GFR, FMD, systolic blood pressure, and fasting blood glucose (FBG). Multivariate analysis indicated that increased visfatin (r = -0.331, P <0.001), baseline GFR (r = -0.234, P = 0.001), FMD (r = 0.163, P = 0.015), and FBG (r = -0.160, P = 0.015) are independent predictors of ΔeGFR/y. Cox regression model analysis showed that visfatin (hazard ratio (HR), 1.09; 95% confidence interval (CI), 1.05-1.13, P <0.001), FBG (HR, 1.01; 95% CI, 1.00-1.02, P = 0.020), and FMD (HR, 0.87; 95% CI, 0.76-1.00, P = 0.049) were independently associated with the risk of developing future renal events. CONCLUSIONS: Increased circulating visfatin are associated with subsequent decline in renal function in nondiabetic hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2015) conducted a cohort in nondiabetic, non-proteinuric hypertension (n=200). Plasma visfatin concentration was evaluated on occurrence of renal events including doubling of Scr, 25% loss of glomerular filtration rate (GFR) from baseline values, and the occurrence of end-stage renal disease (HR 1.09, 95% CI 1.05-1.13, p=<0.001). Increased circulating visfatin was independently associated with the risk of developing future renal events in nondiabetic hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: